Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.
Join us as we dived into four pivotal studies:
frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities.
POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice?
High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols.
EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.
Podden och tillhörande omslagsbild på den här sidan tillhör
Oncology Brothers. Innehållet i podden är skapat av Oncology Brothers och inte av,
eller tillsammans med, Poddtoppen.
